Anat Globerson Levin

469 total citations
20 papers, 370 citations indexed

About

Anat Globerson Levin is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Anat Globerson Levin has authored 20 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Anat Globerson Levin's work include CAR-T cell therapy research (14 papers), Immunotherapy and Immune Responses (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). Anat Globerson Levin is often cited by papers focused on CAR-T cell therapy research (14 papers), Immunotherapy and Immune Responses (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). Anat Globerson Levin collaborates with scholars based in Israel, United States and China. Anat Globerson Levin's co-authors include Zelig Eshhar, Tova Waks, Galit Horn, Isabelle Rivière, Michel Sadelain, Irit Avivi, Koret Hirschberg, Pnina Rotman‐Pikielny, Paul M. Yen and Anat Aharon and has published in prestigious journals such as Nature Communications, Blood and The Journal of Immunology.

In The Last Decade

Anat Globerson Levin

20 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anat Globerson Levin Israel 11 226 183 135 104 45 20 370
Ashwini Balakrishnan United States 5 347 1.5× 202 1.1× 114 0.8× 116 1.1× 91 2.0× 7 448
Tamara Ouspenskaia United States 4 195 0.9× 201 1.1× 100 0.7× 68 0.7× 80 1.8× 5 413
Zhen Jin China 8 177 0.8× 117 0.6× 65 0.5× 134 1.3× 59 1.3× 19 342
Tania Rodríguez-Cruz United States 10 300 1.3× 136 0.7× 189 1.4× 74 0.7× 49 1.1× 14 397
Siobhán Cleary Ireland 6 200 0.9× 143 0.8× 78 0.6× 70 0.7× 107 2.4× 8 420
Cindy A. Chang United States 8 265 1.2× 153 0.8× 93 0.7× 112 1.1× 84 1.9× 10 370
Ruirui Jing China 11 198 0.9× 138 0.8× 88 0.7× 57 0.5× 47 1.0× 19 345
Malvina Prapa Italy 7 198 0.9× 139 0.8× 87 0.6× 83 0.8× 47 1.0× 10 350
Claudia C. Bippes Germany 10 288 1.3× 158 0.9× 177 1.3× 82 0.8× 60 1.3× 13 453
Sanaz Taromi Germany 9 305 1.3× 156 0.9× 139 1.0× 77 0.7× 62 1.4× 13 422

Countries citing papers authored by Anat Globerson Levin

Since Specialization
Citations

This map shows the geographic impact of Anat Globerson Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anat Globerson Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anat Globerson Levin more than expected).

Fields of papers citing papers by Anat Globerson Levin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anat Globerson Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anat Globerson Levin. The network helps show where Anat Globerson Levin may publish in the future.

Co-authorship network of co-authors of Anat Globerson Levin

This figure shows the co-authorship network connecting the top 25 collaborators of Anat Globerson Levin. A scholar is included among the top collaborators of Anat Globerson Levin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anat Globerson Levin. Anat Globerson Levin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horn, Galit, et al.. (2025). Volumetric Nanodroplet‐Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform. Small. 21(23). e2411474–e2411474. 4 indexed citations
2.
Levin, Anat Globerson, Galit Horn, Tova Waks, et al.. (2025). Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Translational Medicine. 14(6). 1 indexed citations
3.
Horn, Galit, et al.. (2023). Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions. Cells. 12(18). 2261–2261. 4 indexed citations
4.
Horn, Galit, Anat Globerson Levin, Sigi Kay, et al.. (2023). The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy. Cancers. 15(23). 5611–5611. 4 indexed citations
5.
Levin, Anat Globerson, Galit Horn, Tova Waks, et al.. (2023). Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease. Blood. 142(Supplement 1). 4833–4833. 1 indexed citations
6.
Horn, Galit, Tova Waks, Ido Laskov, et al.. (2022). Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines. 10(9). 2216–2216. 9 indexed citations
7.
Laskov, Ido, Tova Waks, Nadav Michaan, et al.. (2022). Intra-peritoneal CAR-T cell therapy shows promising results in a murine model of epithelial ovarian cancer (313). Gynecologic Oncology. 166. S164–S164. 2 indexed citations
8.
Rousso-Noori, Liat, Tova Waks, Anat Globerson Levin, et al.. (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications. 12(1). 3615–3615. 31 indexed citations
9.
Aharon, Anat, et al.. (2021). Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. Human Gene Therapy. 32(19-20). 1224–1241. 46 indexed citations
10.
Katz, Ben‐Zion, Ronen Gabizon, Amit Shraga, et al.. (2021). Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. Frontiers in Oncology. 11. 646971–646971. 13 indexed citations
11.
Levin, Anat Globerson, Isabelle Rivière, Zelig Eshhar, & Michel Sadelain. (2021). CAR T cells: Building on the CD19 paradigm. European Journal of Immunology. 51(9). 2151–2163. 43 indexed citations
12.
Horev, Guy, Galit Denkberg, Yael Elbaz‐Alon, et al.. (2021). Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response. Molecular Cancer Therapeutics. 20(5). 872–884. 34 indexed citations
13.
Levin, Anat Globerson, et al.. (2021). T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields. The Journal of Immunology. 207(2). 709–719. 21 indexed citations
14.
Levin, Anat Globerson, et al.. (2020). Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach. Cancer Immunology Immunotherapy. 69(7). 1165–1175. 11 indexed citations
15.
Levin, Anat Globerson, Tova Waks, Galit Horn, et al.. (2020). Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. Cancer Immunology Research. 8(12). 1485–1495. 30 indexed citations
16.
Levin, Anat Globerson, Zelig Eshhar, Niv Pencovich, et al.. (2019). P12.05 Evaluating the compatibility of tumor treating electric fields with key antitumoral immune functions. Neuro-Oncology. 21(Supplement_3). iii60–iii60. 1 indexed citations
17.
Zupančič, Eva, Caterina Curato, Jung‐Seok Kim, et al.. (2018). Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine Nanotechnology Biology and Medicine. 14(3). 835–847. 17 indexed citations
18.
Zigler, Maya, Alexei Shir, Shoshana Klein, et al.. (2016). HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment. Cancer Immunology Research. 4(8). 688–697. 8 indexed citations
19.
Levin, Anat Globerson, Tova Waks, & Zelig Eshhar. (2014). Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor-Modified T Cells. Molecular Therapy. 22(5). 1029–1038. 46 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashwini Balakrishnan Breakdown of academic impact, for papers by Tamara Ouspenskaia Breakdown of academic impact, for papers by Zhen Jin Breakdown of academic impact, for papers by Tania Rodríguez-Cruz Breakdown of academic impact, for papers by Siobhán Cleary Breakdown of academic impact, for papers by Cindy A. Chang Breakdown of academic impact, for papers by Ruirui Jing Breakdown of academic impact, for papers by Malvina Prapa Breakdown of academic impact, for papers by Claudia C. Bippes Breakdown of academic impact, for papers by Sanaz Taromi
Rankless by CCL
2026